Pharmacokinetics and residue depletion of erythromycin in gilthead sea bream Sparus aurata L. after oral administration

© 2013 John Wiley & Sons Ltd.

Bibliographische Detailangaben
Veröffentlicht in:Journal of fish diseases. - 1998. - 37(2014), 9 vom: 01. Sept., Seite 797-803
1. Verfasser: Di Salvo, A (VerfasserIn)
Weitere Verfasser: Pellegrino, R M, Cagnardi, P, della Rocca, G
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Journal of fish diseases
Schlagworte:Journal Article Research Support, Non-U.S. Gov't erythromycin pharmacokinetics residue sea bream (N-methyl) erythromycin Anti-Bacterial Agents Erythromycin 63937KV33D
LEADER 01000naa a22002652 4500
001 NLM230460135
003 DE-627
005 20231224084456.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.1111/jfd.12170  |2 doi 
028 5 2 |a pubmed24n0768.xml 
035 |a (DE-627)NLM230460135 
035 |a (NLM)23992037 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Di Salvo, A  |e verfasserin  |4 aut 
245 1 0 |a Pharmacokinetics and residue depletion of erythromycin in gilthead sea bream Sparus aurata L. after oral administration 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 30.03.2015 
500 |a Date Revised 30.09.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2013 John Wiley & Sons Ltd. 
520 |a Erythromycin (ERY) is an antibiotic effective against Streptococcus iniae, a microorganism responsible for significant losses in aquaculture. No data are available on the pharmacokinetics and residue depletion of ERY in sea bream. The aim of this study was thus to evaluate the pharmacokinetics of ERY in this species after a single oral administration at 75 mg kg(-1) b.w. and to assess its residue depletion from tissues after prolonged treatment for 10 days. ERY was rapidly absorbed in sea bream (Cmax  = 10.04 μg g(-1) and Tmax =1 h), with a half-life of 9.35 h and an AUC0-24 of 56.81 (h μg mL(-1) ). The data obtained and the evaluation of pharmacokinetic/pharmacodynamic parameters allowed us to hypothesize that dosage used in this study should be effective against S. iniae. A rapid reduction in erythromycin concentrations was observed in tissues, with the drug being detectable only during the first day post-treatment. In Europe, the use of ERY in aquaculture is allowed by off-label prescription with a withdrawal time of 500 °C day(-1) . The absence of ERY residues in tissues already at 24 h post-treatment suggests that ERY in sea bream should not pose human food safety issues 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a erythromycin 
650 4 |a pharmacokinetics 
650 4 |a residue 
650 4 |a sea bream 
650 7 |a (N-methyl) erythromycin  |2 NLM 
650 7 |a Anti-Bacterial Agents  |2 NLM 
650 7 |a Erythromycin  |2 NLM 
650 7 |a 63937KV33D  |2 NLM 
700 1 |a Pellegrino, R M  |e verfasserin  |4 aut 
700 1 |a Cagnardi, P  |e verfasserin  |4 aut 
700 1 |a della Rocca, G  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Journal of fish diseases  |d 1998  |g 37(2014), 9 vom: 01. Sept., Seite 797-803  |w (DE-627)NLM098166034  |x 1365-2761  |7 nnns 
773 1 8 |g volume:37  |g year:2014  |g number:9  |g day:01  |g month:09  |g pages:797-803 
856 4 0 |u http://dx.doi.org/10.1111/jfd.12170  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 37  |j 2014  |e 9  |b 01  |c 09  |h 797-803